Post-earnings recap
Reported
Thu, Feb 6, 2025
EPS actual
$1.69
EPS est.
$1.57
EPS surprise
+7.51%
1-day move
-0.46%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Neurocrine Biosciences reported better-than-expected earnings per share, but the stock fell slightly by 0.46%. Investors may be cautious due to the lack of revenue guidance and the overall market sentiment. The positive EPS surprise indicates some operational strength, but uncertainty remains regarding future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.69 | N/A | +7.51% |
| Revenue | N/A | N/A | N/A |
Management expressed satisfaction with the EPS results, highlighting operational efficiencies. However, they did not provide specific revenue guidance.
We are pleased with our EPS performance this quarter.
While we did not provide revenue guidance, we remain focused on our strategic initiatives.